New data from TWILIGHT – a Phase IV independent trial funded by AstraZeneca – showed that in patients at high-bleeding risk who underwent PCI and completed three months of dual antiplatelet therapy, Brilinta monotherapy (90 mg twice daily) reduced the risk of BARC (Bleeding Academic Research Consortium) type 2, 3 or 5 bleeding compared to Brilinta plus low-dose aspirin after 12 months.
Daiichi Sankyo Company Limited announced results from ENTRUST-AF PCI, the first large randomized study to evaluate the efficacy and safety of once-daily edoxaban (known by the brand name Lixiana) plus a P2Y12 inhibitor against a regimen of vitamin K antagonist plus P2Y12 inhibitor and acetyl salicylic acid in atrial fibrillation patients following successful percutaneous coronary intervention.
